29/03/2021at 09:32

Orphazyme fails trial in muscle wasting disease

Orphazyme's drug arimoclomol has not shown the desired effect in a pivotal phase II/III trial involving 150 patients with inclusion body myositis (IBM).

BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN

On Monday morning, Orphazyme was forced to announce that the firm had not seen the results from the phase II/III trial with arimoclomol as treatment for inclusion body myositis (IBM) for which the company management had hoped.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles
Receive our daily newsletters
Access our app

Get full access for you and your coworkers

Start a free company trial today

Orphazyme CFO: 2021 will be the decisive year
For subscribers
Orphazyme: Anticipated product approval to secure transformational year
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Front page now

Pharma & biotech

Adolescent patients' eczema improved in Leo Pharma's late-stage testing

Two phase III trials give the Danish dermatology company hope to see tralokinumab’s approved indication expanded to include the younger segment of teens.

For subscribers

Hearing health

DNB surprised by GN's lack of backup plan

For subscribers

Pharma & biotech

Leo Pharma presents positive data in hand eczema phase III trial

For subscribers

Foto: Guillaume Souvant/Reuters/Ritzau Scanpix

Pharma & biotech

Six-month Ozempic shortage mostly over after weight-loss craze drained supply

For subscribers

Foto: Tingshu Wang/Reuters/Ritzau Scanpix

Regulation

Competition sharpens on active ingredient production – EU weighs measures

For subscribers

Pharma & biotech

Wegovy prescriptions in the US grow for another week

For subscribers

Novo Nordisk reacts to suspension: "We take the decision very seriously"

Novo Nordisk, which has been ousted from UK pharma group ABPI for two years, does not want to comment further on its punishment for misleading marketing.

For subscribers

Hearing health

DNB surprised by GN's lack of backup plan

The lack of support for GN’s scrapped capital raise was to be anticipated, says a DNB analyst, meaning it would have made sense to make a plan B in advance.

For subscribers

Foto: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix

Pharma & biotech

UK pharma group suspends Novo Nordisk for two years

Novo Nordisk has been suspended due to misleading marketing that breached the Code of Practice of the Association of the British Pharmaceutical Industry.

For subscribers